%0 Figure %A E. Ware, Kathryn %A E. Marshall, Marianne %A R. Heasley, Lydia %A Marek, Lindsay %A K. Hinz, Trista %A Hercule, Paula %A A. Helfrich, Barbara %A C. Doebele, Robert %A E. Heasley, Lynn %D 2010 %T Induction of FGFR2 and FGFR3 mRNA and protein in EGFR inhibitor treated NSCLC cells. %U https://plos.figshare.com/articles/figure/_Induction_of_FGFR2_and_FGFR3_mRNA_and_protein_in_EGFR_inhibitor_treated_NSCLC_cells_/486775 %R 10.1371/journal.pone.0014117.g001 %2 https://plos.figshare.com/ndownloader/files/816424 %K fgfr2 %K fgfr3 %K mrna %K egfr %K inhibitor %K treated %K nsclc %X

A. Quantitative RT-PCR assay for FGFR2 and FGFR3 mRNAs. Total RNA was purified from the indicated cell lines following a 3-day treatment with 1 µM gefitinib and submitted to quantitative RT-PCR analysis of FGFR2, FGFR3 and GAPDH. (Cell lines with EGFR autocrine signaling or gain-of-function EGFR mutations: open bars; cell lines lacking EGFR signaling: grey bars) The data are presented as fold expression over DMSO treated cells following normalization for GAPDH mRNA. B–C. Cell lysates from the indicated NSCLC cell lines treated 3 days with or without 1 µM gefitinib or 2 µg/mL Erbitux were immunoblotted for FGFR2, FGFR3, EGFR and the α-subunit of the NaK-ATPase as a loading control. Densitometry of FGFR2, FGFR3 and EGFR expression was normalized relative to NaK-ATPase expression and is indicated under each immunoblot.

%I PLOS ONE